CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer

NCT01583686 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

15

Enrollment

NIH

Sponsor class

Stopped Study terminated due to slow/insufficient accrual.

Conditions

Cervical Cancer
Pancreatic Cancer
Ovarian Cancer
Mesothelioma
Lung Cancer

Interventions

DRUG: Fludarabine
BIOLOGICAL: Anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL)
DRUG: Cyclophosphamide
DRUG: Aldesleukin

Sponsor

National Cancer Institute (NCI)